| Document |
Document Title |
|
WO/2024/095296A1 |
The present invention relates to solvent free compositions, more particularly, compositions containing self-emulsifying amorphous solid dispersion resulting in pharmaceutical compositions with enhanced solubility and thereby enhanced bio...
|
|
WO/2024/094190A1 |
The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune dis...
|
|
WO/2024/092895A1 |
Disclosed is a method for preparing 2,4,5-triamino-6-hydroxypyrimidine sulfate by means of a micro-channel reaction. Specifically, 2,4-diamino-6-hydroxypyrimidine is taken as a raw material, and after a cyclization reaction at a proper s...
|
|
WO/2024/095268A1 |
Methods for treating or reducing inflammation, in is in a site or an organ excluding the central nervous system of a subject in need thereof, by administering a pharmaceutical composition comprising the translocator protein ligand 2-C1-M...
|
|
WO/2024/097219A1 |
The disclosure relates to method for treating, among other things, NF1 or conditions resulting from NF1 function loss the method comprising administering a therapeutically effective amount of (i) a single selective RXR agonist; or (ii) t...
|
|
WO/2024/091498A1 |
Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral c...
|
|
WO/2024/064214A3 |
The present disclosure provides methods of preparing substituted cyclopropane compounds.
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/073073A3 |
The invention provides compounds that modulate the activity of protein kinases that are associated with human diseases, disorders, and conditions. In particular, compounds of the invention inhibit LRRK2.
|
|
WO/2024/091024A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/064721A3 |
The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic dise...
|
|
WO/2024/087265A1 |
A protein inhibitor, a reagent set, and a use thereof. The protein inhibitor is an inhibitor for inhibiting a CILK1 protein; the protein inhibitor is CILK1-C28 or CILK1-C30; the use of the protein inhibitor is to apply the protein inhibi...
|
|
WO/2024/083256A1 |
Provided in the present invention are a pan-KRAS degrading agent, and a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a small molecule compound for targeted degradation of the pan-K...
|
|
WO/2024/086789A2 |
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2024/086347A1 |
This disclosure features methods for the rational design of Cereblon-based molecular glue degraders. Also featured are methods for the rational and modular design of MGDs. The methods include selecting a plurality of organic moieties, al...
|
|
WO/2024/083258A1 |
Disclosed in the present invention are a KRAS G12C degradation agent, and a preparation method and use therefor. The KRAS G12C degradation agent in the present invention is a compound as shown in formula I or I', and/or a stereoisomer, e...
|
|
WO/2024/085676A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same, and, more specifically, to an organic compound having excellent electron injection and transport ability and thermal stability...
|
|
WO/2024/078372A1 |
Provided are a heterocyclic substituted phenol derivative, a preparation method therefor, and a use thereof. Specifically, provided are compounds of formulas (I-1), (II-1B), (III), and (IV), stereoisomers thereof, pharmaceutically accept...
|
|
WO/2024/078906A1 |
The present invention relates to substituted N-phenyluracils of general formula (I) or salts thereof (formula I), wherein the radicals in general formula (I) correspond to the definitions given in the description, and to the use thereof ...
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
|
WO/2024/078555A1 |
The present invention relates to the field of drugs, and specifically, the present invention relates to a pyrimidopyridine compound, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a compo...
|
|
WO/2024/080844A1 |
The present disclosure relates to a novel pyrimidine derivative, a solvate or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including any of the foregoing as an active ingredient, t...
|
|
WO/2024/077085A1 |
The present disclosure describes methods of treating a condition comprising administering a compound that inhibits PLA2G7. The present disclosure describes methods of treating a condition comprising administering a compound that inhibits...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/074577A1 |
The present disclosure relates to methods of preparing a compound of Formula (IX): (IX); or a pharmaceutically acceptable salt thereof. The present disclosure also relates to compounds being prepared by the methods, the pharmaceutical co...
|
|
WO/2024/074538A1 |
The present disclosure relates to morphic forms of Compound A. The present disclosure also relates to processes for the preparation of the morphic forms of Compound A, the pharmaceutical compositions comprising the morphic forms, and the...
|
|
WO/2024/067626A1 |
A composite, comprising: 3-hydroxybutyric acid; and one or more of potassium 3-hydroxybutyrate, or calcium 3-hydroxybutyrate, or magnesium 3-hydroxybutyrate. A composite, wherein the anion comprises 3-hydroxyvaleric acid, and the cation ...
|
|
WO/2024/069507A1 |
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphe
nyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
|
WO/2024/073502A1 |
The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/064091A1 |
This present invention relates to compounds of Formula I that feature the inhibition of protein tyrosine kinases (PTKs), including EGFR mutants, their pharmaceutical compositions that comprising a therapeutically effective amount of the ...
|
|
WO/2024/064024A1 |
The present invention relates to ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives of formula (I) as well as to said compounds for use as P13K inhibitors in methods of treatment of cancer.
|
|
WO/2024/064214A2 |
The present disclosure provides methods of preparing substituted cyclopropane compounds.
|
|
WO/2024/062479A1 |
The present disclosure relates to a process for the preparation of a brominated uracil derivative of Formula I, wherein R1, R2 and R3 are independently selected from H, and branched or unbranched alkyl group having C1-C7, said process co...
|
|
WO/2024/061365A1 |
Provided are a compound represented by formula (I), or a tautomer, a cis-trans isomer, a mesomer, a racemate, an enantiomer, a diastereomer, or an atropisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt, a s...
|
|
WO/2024/058311A1 |
The present invention relates to a method for producing ectoine, the method being charcteriezed by comprising: a step for producing (2-nosyl)-L-glutamine by introducing a nosyl group into L-glutamine as a protecting group; a step for pro...
|
|
WO/2024/057001A1 |
The present invention relates to compounds of Formula (I) that may act as agonists of retinoic acid receptor alpha (RAR-α) and/or retinoic acid receptor beta (RAR-β). The invention also relates to pharmaceutical compositions comprising...
|
|
WO/2024/059010A1 |
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
|
|
WO/2024/059668A2 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit epidermal growth factor receptor (EGFR), the methods of maki...
|
|
WO/2024/050825A1 |
A substituted cyclic compound as represented by formula (I) and having a selective inhibitory effect on MLKL, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing ...
|
|
WO/2024/054997A1 |
Provided herein are methods to treat rhegmatogenous retinal detachment (RRD) and/or improve visual outcomes of RRD.
|
|
WO/2024/050366A1 |
Described herein are methods, devices, and systems for identifying a subset of a plurality of features, using one or more feature importance metrics, for training and using a homologous repair deficiency (HRD) classification model. Furth...
|
|
WO/2024/047648A1 |
The present invention relates to a novel nitration process of 2- chloro-4- fluorobenzoic acid or alkyl 2-chloro-4- fluorobenzoate, using oleum and nitric acid, to obtain 2-chloro-4- fluoro-5- nitrobenzoic acid or alkyl 2-chloro-4-f luoro...
|
|
WO/2024/045747A1 |
The present application belongs to the technical field of organic materials, and provides an organic compound, an electronic component and an electronic device. The structure of the organic compound is as shown in formula (1), and there ...
|
|
WO/2024/040497A1 |
An antiviral compound, a preparation method therefor and an use thereof; specifically an anti-coronavirus compound that can be used as a PLPro inhibitor, a preparation method therefor and a use thereof. The compound has a structure repre...
|
|
WO/2024/044757A1 |
The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
|
